The updated Medscheme specialised drug list for...

By HEOR Staff Writer

May 12, 2023

Reimbursement is still dependent on authorisation and benefit limits. Some drugs included: ANTIHEMORRHAGICS Hemlibra CARDIOVASCULAR SYSTEM Volibris DERMATOLOGICALS Dupixent ANTIVIRALS FOR SYSTEMIC USE Epclusa ANTINEOPLASTIC AGE...
Equity in Global Health Research: Lessons from the 8Quity Tool
Addressing Concerns for Successful Implementation of National Health Insuranc...
WHO Identifies Emerging Innovations in Global Health
Political Economy Analysis Reveals Challenges Facing Primary Health Care in E...
ICER, CADTH, and NICE collaborate to increase transparency in health technolo...
Prioritizing Mental Health in South African Medical Schemes: Challenges and O...
ICER Report on Lecanemab: Efficacy, Cost, and Equity Concerns for Alzheimer&#...
Update on the HTA Coordination Group subgroup meetings held on April 25 and 26
New Preferred Characteristics for Monoclonal Antibodies in Malaria Prevention
Tezepelumab as an Add-on Maintenance Treatment for Severe Asthma: Recommendat...
Clinical evidence shows that AposHealth (an FDA-cleared medical device) impro...
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Go...